CD33 and acute myeloid leukemia: Huang and colleagues presented preliminary data from a phase I study on multiple infusions of allogeneic CAR-NK cells targeting CD33 in 10 patients with relapsed/refractory AML, reporting no toxicity, and 6 out of 10 patients achieved MRD-negative complete remission by day 28 (208).